Abstract:5567 Background: Studies have suggested that estrogen regulates the malignant transformation of ovarian surface epithelial cells, stimulates the growth and migration of cancer cells. and promotes the VEGF expression in epithelial ovarian cancer. Anlotinib is a novel multi-target tyrosine kinase inhibitor, inhibiting tumor angiogenesis and proliferative signaling. In this study, we evaluate the activity of anlotinib combined with letrozole in patients with estrogen receptor positive, platinum-resistant recurrent ovarian carcinoma (NCT04720807). Methods: Patients who have previously received two or more chemotherapy treatments, with histopathologically confirmed high-grade serous ovarian cancer (including salpingo carcinoma and peritoneal carcinoma), estrogen receptor (ER) positive and ECOG 0-2 were considered eligible for enrollment. Anlotinib was taken orally (10mg mg qd, d1-14, 21 days per cycle), and letrozole was taken orally (2.5mg qd, d1-21, 21 days per cycle). The treatment was continued until disease progression, death, or intolerant toxicity. The primary endpoint was objective response rate (ORR) and the secondary endpoints included disease control rate (DCR), duration of remission (DOR) progression free survival (PFS), overall survival (OS) and safety. Results: Between September 2020 and December 2023, 30 patients with a median age of 61 years (range:50-79), FIGO histopathological stage I (11.1%), II(3.7%), III (59.3%) and IV (25.9%) were enrolled. Twenty-seven of these patients have been evaluated for efficacy. In the efficacy-evaluable population (n=12), the therapeutic evaluation showed that 7 and 13 patients achieved partial response and Stable disease respectively(with the standards of GCIC), yielding the ORR of 16.7% (7/27 95% CI: 11.8% to 46.6%). The DCR was 74.1% (20/27, 95% CI: 53.4% to 88.1%). The median PFS was 4.24 months (95% CI: 3.71m to 5.09m) and the median OS was 18.96 months (95% CI: 8.34m to 31.05m).With subgroup analyses, Patients who had received PARPi before and patients with baseline CA125 level >500 had significant prolongations in mOS and mPFS, respectively. The most common adverse events (AEs) were grade 1 or 2, which included laryngitis (44.4%), stomatitis (37.0%), hand-foot syndrome (29.6%), and fatigue (25.9%), diarrhea (22.2%), hypertension (14.8%),. The grade 3 AEs were hypertension (37.0%), hand-foot syndrome (3.7%), diarrhea (3.7%) and hyperuricemia (3.7%). No higher AEs or treatment-related death were observed. Conclusions: As a chemo-free regimens, anlotinib plus letrozole showed a promising efficacy with a favorable toxicity profile for patients with platinum-resistant recurrent ovarian cancer. Research Sponsor: Chia Tai Tianqing Pharmaceutical Group Co. GYNECOLOGIC CANCER. Clinical trial information: NCT04720807 .

Anlotinib induces apoptosis and second growth/mitosis phase block in cisplatin-resistant ovarian cancer cells via the aurora kinase A/p53 pathway

Anlotinib Inhibits Ovarian Cancer and Enhances Cisplatinum SensitivityviaSuppressing NOTCH2 Expression and Stemness

Anlotinib Inhibits Ovarian Cancer and Enhances Cisplatinum Sensitivity via Suppressing NOTCH2 Expression and Stemness

Anlotinib in Patients with Recurrent Platinum Resistant/refractory Ovarian Cancer: a Prospective, Single Arm, Phase II Study.

Anlotinib in Patients with Recurrent Platinum-Resistant or Refractory Ovarian Carcinoma: A Prospective, Single-Arm, Single-Center, Phase II Clinical Study.

Aurora Kinase A Inhibition Potentiates Platinum and Radiation Cytotoxicity in Non-Small-Cell Lung Cancer Cells and Induces Expression of Alternative Immune Checkpoints

Anlotinib Combined with Pemetrexed As a Further Treatment of Patients with Platinum-Resistant Ovarian Cancer: A Single-Arm, Open-Label, Phase II Study

Anlotinib plus hormone therapy in patients with platinum-resistant recurrent ovarian cancer: A prospective, single-arm, open-label, phase II study.

Anlotinib Plus Letrozole in Patients with Platinum-Resistant Recurrent Ovarian Cancer: A Prospective, Single-Arm, Open-Label, Phase II Study.

Synergistic Effects of Anlotinib and DDP Synergy in Breast Cancer Treatment: Inhibiting of Cell Growth and Migration, and Augmenting Apoptosis and Autophagy Via Modulation of the VEGF/JAK2/STAT3 Axis

The involvement of Bcl-2 family proteins in AKT-regulated cell survival in cisplatin resistant epithelial ovarian cancer

Alisertib, an Aurora Kinase A Inhibitor, Induces Apoptosis and Autophagy but Inhibits Epithelial to Mesenchymal Transition in Human Epithelial Ovarian Cancer Cells

Anlotinib Combined with TQB2450 in Patients with Platinum-Resistant or -Refractory Ovarian Cancer: A Multi-Center, Single-Arm, Phase 1b Trial.

Anlotinib Inhibits The Progress Of Colorectal Cancer Cells By Antagonizing Glycolysis & Jak2-Stat3 Signaling

Anlotinib Inhibits the Growth of Breast Cancer Cells by Promoting Autophagy and Apoptosis Via the Akt/GSK-3α Signalling Pathway

Anlotinib Overcomes Multiple Drug Resistant Colorectal Cancer Cells via Inactivating PI3K/AKT Pathway

Anlotinib Combined with Carboplatin/paclitaxel and Maintenance Anlotinib As Front-Line Treatment for Newly Diagnosed Advanced Ovarian Cancer: A Phase II, Single-Arm, Multi-Center Study (ALTER-GO-010)

Targeting the Cdc2-like kinase 2 for overcoming platinum resistance in ovarian cancer

Anlotinib (AL3818) Plus Pemetrexed in Patients with Recurrent Platinum-Resistant Advanced Epithelial Ovarian Cancer: A Single-Arm, Open-Label, Phase II Study.

Sequential treatment with aurora B inhibitors enhances cisplatin-mediated apoptosis via c-Myc

Synergistic Effects of Anlotinib and DDP on Breast Cancer: Targeting the VEGF/JAK2/STAT3 Axis